Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report
Jean Bousquet,Mohamed H Shamji,Josep M Anto,Holger J Schünemann,G Walter Canonica,Marek Jutel,Stefano Del Giacco,Torsten Zuberbier,Oliver Pfaar,Joao A Fonseca,Bernardo Sousa-Pinto,Ludger Klimek,Wienczyslawa Czarlewski,Anna Bedbrook,Rita Amaral,Ignacio J Ansotegui,Sinthia Bosnic-Anticevich,Fulvio Braido,Claudia Chaves Loureiro,Bilun Gemicioglu,Tari Haahtela,Marek Kulus,Piotr Kuna,Maciej Kupczyk,Paolo M Matricardi,Frederico S Regateiro,Boleslaw Samolinski,Mikhail Sofiev,Sanna Toppila-Salmi,Arunas Valiulis,Maria Teresa Ventura,Cristina Barbara,Karl C Bergmann,Michael Bewick,Hubert Blain,Matteo Bonini,Louis-Philippe Boulet,Rodolphe Bourret,Guy Brusselle,Luisa Brussino,Roland Buhl,Victoria Cardona,Thomas Casale,Lorenzo Cecchi,Denis Charpin,Ivan Cherrez-Ojeda,Derek K Chu,Cemal Cingi,Elisio M Costa,Alvaro A Cruz,Philippe Devillier,Stephanie Dramburg,Wytske J Fokkens,Maia Gotua,Enrico Heffler,Zhanat Ispayeva,Juan Carlos Ivancevich,Guy Joos,Igor Kaidashev,Helga Kraxner,Violeta Kvedariene,Désirée E Larenas-Linnemann,Daniel Laune,Olga Lourenço,Renaud Louis,Mika Makela,Michael Makris,Marcus Maurer,Erik Melén,Yann Micheli,Mario Morais-Almeida,Joaquim Mullol,Marek Niedoszytko,Robyn O'Hehir,Yoshitaka Okamoto,Heidi Olze,Nikolaos G Papadopoulos,Alberto Papi,Vincenzo Patella,Benoit Pétré,Nhân Pham-Thi,Francesca Puggioni,Santiago Quirce,Nicolas Roche,Philip W Rouadi,Ana Sá-Sousa,Hironori Sagara,Joaquin Sastre,Nicola Scichilone,Aziz Sheikh,Milan Sova,Charlotte Suppli Ulrik,Luis Taborda-Barata,Ana Todo-Bom,Maria J Torres,Ioanna Tsiligianni,Omar S Usmani,Erkka Valovirta,Tuula Vasankari,Rafael José Vieira,Dana Wallace,Susan Waserman,Mihaela Zidarn,Arzu Yorgancioglu,Luo Zhang,Tomas Chivato,Markus Ollert
DOI: https://doi.org/10.1111/all.15740
IF: 12.4
Allergy
Abstract:Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.